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Purpose: Previous studies have described a possible association between exfoliation syndrome (EX) and various ocular
and systemic vascular disorders; however, the association between EX and branch retinal vein occlusion (BRVO) remains
unclear. Because slit-lamp examination may overlook latent deposits of exfoliation materials, an ocular biopsy is usually
needed for a precise diagnosis. We evaluated a possible association between EX and BRVO using lysyl oxidase-like 1
(LOXL1) gene variants as alternative markers for EX.
Methods: Allelic and genotypic frequencies of three LOXL1 variants (rs1048661, rs3825942, and rs2165241) were
determined for 78 consecutive Japanese patients with BRVO (11 patients with exfoliation syndrome [EX+], 67 patients
without exfoliation syndrome [EX-]), and 158 patients with cataract without EX (CT) as controls.
Results: The rs1048661 variant differed between the BRVO and CT groups in allelic and genotypic frequencies (p=0.0137
and p=0.0203, respectively). Subgroup analysis, compared to the CT group, showed that BRVO EX+ had significantly
different allelic and genotypic frequencies of rs1048661 (p=0.00011 and p=0.000189, respectively), while BRVO EX-
did not (p=0.175 and p=0.288, respectively). The frequencies of rs3825942 and rs2165241 did not differ between the
BRVO and CT groups.
Conclusions: No association was found between BRVO and EX if LOXL1 variants were used as disease markers for
clinically undetectable EX. The results suggested that LOXL1 variants, well established markers for EX, are not likely
genetic markers for BRVO in Japanese subjects.
Retinal vein occlusions (RVOs), including central retinal
vein occlusion (CRVO), an occlusion at the central trunk of
the retinal vein, and branch retinal vein occlusion (BRVO),
an occlusion at an arteriovenous crossing where the retinal
artery and vein are bound by a common adventitial sheath, are
important causes of ocular morbidity [1,2]. Although CRVO
and BRVO have several risk factors in common, including
systemic  hypertension,  smoking,  hyperlipidemia,  and
elevated plasma homocysteine [1,2], they do not fully explain
the involvement of the central trunk or branch of the retinal
vein circulation.
Exfoliation  syndrome  (EX),  the  most  common
identifiable cause of open-angle glaucoma worldwide, is an
age-related, generalized disorder of the extracellular matrix
characterized by the production and progressive accumulation
of fibrillar extracellular material in many ocular tissues [3]. A
recent  genome-wide  association  study  reported  that  one
intronic single nucleotide polymorphism (SNP; rs2165241)
and  two  exonic  SNPs  (rs1048661  [R141L],  rs3825942
[G153D])  in  the  first  exon  of  the  lysyl  oxidase-like  1
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(LOXL1) gene on chromosome 15q24.1 are highly associated
with EX in Icelandic and Swedish populations, and that none
of  these  SNPs  was  associated  with  primary  open-angle
glaucoma in the two populations [4]. Several studies have
confirmed the association of these SNPs with EX in other
populations [5], including a Japanese population [6-11].
In addition to ocular tissues, production and progressive
accumulation  of  exfoliation  materials  occur  in  skin  and
various visceral organs [3,12]. The association of EX with
various systemic vascular and neurodegenerative disorders
has been described in ischemic heart disease [13,14], carotid
stiffness  [15],  cerebrovascular  disease  [16],  Alzheimer
disease [17], and hearing loss [18]. Regarding RVO, several
studies have described a possible association between CRVO
and  EX  diagnosed  based  on  chart  review  [19],  slit-lamp
examination [20], histopathologic studies in enucleated eyes
[21,22],  and  a  combination  of  slit-lamp  examination  and
conjunctival  biopsy  [23],  while  only  a  few  studies  have
evaluated the association between BRVO and EX [19,20].
Recently,  the  role  of  the  LOXL1  polymorphism  has  been
tested in several ocular [24] and systemic [25,26] pathologies
to explore the association between EX and these pathologies,
suggesting the usefulness of analyzing LOXL1 variants as a
disease marker for EX.
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3309In the current study, we tested the association between
LOXL1  variants  and  BRVO  in  a  Japanese  population  to
explore a possible association between EX and BRVO.
METHODS
Subjects: Unrelated Japanese subjects with BRVO (n=78)
were  consecutively  recruited  at  the  Shimane  University
Hospital and Iinan Hospital in Shimane, Japan. The BRVO
group was divided into two subgroups based on the presence
(EX+, n=11) or absence (EX-, n=67) of clinically detectable
ocular deposits of exfoliation material. The data set from
patients with cataract without deposits of exfoliation material
(CT, n=158) reported in our previous study [11] served as a
control. The demographic data including age and gender for
each group are summarized in Table 1.
Methods:  The  current  study  adhered  to  the  tenets  of  the
Declaration of Helsinki. The institutional review boards of
both  hospitals  reviewed  and  approved  the  research.  All
subjects  provided  written  informed  consent.  All  subjects
underwent  a  dilated  pupil  examination  of  the  anterior
segments,  ocular  media,  and  fundus  using  a  slit-lamp
(RO5000,  Buchmann  Deutschland,  Düsseldorf,  Germany)
and a funduscope (BS-III, Neitz Instruments, Tokyo, Japan).
BRVO was diagnosed if the fundus examination revealed
venous dilation and tortuosity with flame-shaped and dot-blot
hemorrhages in a wedge-shaped region. Patients with CRVO
and  hemi-CRVO  were  excluded.  Deposits  of  exfoliation
material were identified if the slit-lamp examination revealed
a typical pattern of exfoliation material on the anterior lens
surface and/or pupillary margin.
DNA  genotyping:  Genomic  DNA  was  extracted  from  the
peripheral white blood cells of each subject. A polymerase
chain  reaction  was  performed  using  primers  designed  to
amplify the genomic region containing both rs1048661 and
rs3825942 (forward primer: 5′-AGG TGT ACA GCT TGC
TCA ACT C-3′ and reverse primer: 5′-TAG TAC ACG AAA
CCC TGG TCG T-3′) or only rs2165241 (forward primer: 5′-
AGA ATG CAA GAC CTC AGC ATG AG-3′ and reverse
primer: 5′-TAG TGG CCA GAG GTC TGC TAA G-3′). The
sequence was determined based on the dideoxy terminator
method  using  an  ABI  PRISM  3130xl  Genetic  Analyzer
(Applied  Biosystems,  Foster  City,  CA)  according  to  the
manufacturer’s protocol. We used SeqScape Software version
2.5 (Applied Biosystems) to analyze the sequence alignment.
Statistical analysis: Statistical analysis was performed using
R version 2.6.2. Fisher’s exact test was used to compare the
allele or genotype frequencies of each group with the controls.
RESULTS
The allelic and genotypic counts and frequencies of SNPs
rs1048661,  rs3825942,  and  rs2165241  within  LOXL1  are
shown in Table 2. Compared to the CT group, the T allele and
TT genotype frequencies of rs1048661 were higher in patients
with  BRVO  (p=0.0137  and  p=0.0203,  respectively).  In
subgroup analysis, compared to the CT group, the group with
BRVO  with  exfoliation  material  deposits  (EX+)  had
significantly  different  allelic  and  genotypic  frequencies
(p=0.00011 and p=0.000189, respectively), while the group
with BRVO without exfoliation material deposits (EX-) had
no difference in allelic and genotypic frequencies (p=0.175
and p=0.288, respectively). Compared to the CT group, the
frequencies of the G allele of rs3825942 and the C allele of
rs2165241  were  higher  in  the  BRVO  EX+  groups  with
borderline  significance  (p=0.0933  and  p=0.0908,
respectively), but the allelic and genotypic frequencies did not
differ between any pairs of BRVO total or BRVO EX- and the
CT group.
DISCUSSION
To the best of our knowledge, this is the first study to identify
a possible association between LOXL1 variants and BRVO.
The prevalence of clinical EX increases with age, especially
after age 60 [3]. Accordingly, detection of exfoliation material
deposits by slit-lamp examination may overlook latent EX.
Indeed, previous studies have suggested that the prevalence
of  exfoliation  material  deposits  found  on  histopathologic
assessment  of  ocular  specimens  was  roughly  double
compared  with  the  slit-lamp  examination  [27,28].  A
conjunctival  biopsy  can  detect  preclinical  EX  that  is  not
evident on slit-lamp examination [23]; however, because the
TABLE 1. SUMMARY OF STUDY POPULATIONS.
  BRVO    
  Total EX- EX+ CT p-value
No. of subjets 78 67 11 158  
Men/Women
No. 32/46 29/38 3/8 45/113 0.0568*
% 41/59 33/67 27/73 28/72  
Age (years)
Mean±SD 73.2±9.6 72±9.4 80.5±6.8 76.9±4.9 5.81×10−5†
Range 47–88 47–87 69–88 70–90  
          *Fisher’s exact probability test between BRVO (total) and CT groups. †Unpaired t-test between BRVO (total) and CT groups.
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3311biopsy is invasive, it cannot be used for all patients. The role
of  the  LOXL1  polymorphism  has  been  tested  in  several
pathologies  including  wet  and  dry  age-related  macular
degeneration  and  polypoidal  choroidal  vasculopathy  in  a
Japanese population [24], Alzheimer disease in a Swedish
population [25], and cardiovascular disease in a Hungarian
population [26]. Fuse et al. found a significant association
between the rs1048661 polymorphism and wet age-related
macular degeneration in a Japanese population [24]. These
studies encouraged us to use the LOXL1 polymorphism as an
alternative marker of clinically undetectable EX other than
invasive biopsy/histopathology.
Among the three SNPs reported [4], rs1048661 has been
consistently suggested as the most significant indicator of EX/
glaucoma in Icelandic, Swedish, and Japanese populations
[6-11]. Accordingly, our results of a significant difference in
allelic and genotypic frequencies of rs1048661 between all
subjects with BRVO and CT or BRVO EX+ and CT groups
confirmed previous observations of the strong role of this SNP
in EX. The results also suggested that using this SNP, we can
detect a case–control association for EX even with such a
small number of subjects (n=11) in a case group. In the same
context, the other two SNPs, which showed only a borderline
difference between BRVO EX+ and CT groups, may not have
enough  discriminatory  power  with  this  small  number  of
subjects.
Since both the BRVO EX- and CT groups, which were
classified based on slit-lamp examination as not having EX,
were identical except for the presence or absence of BRVO,
comparison between these two groups should provide the
most  reliable  information  about  the  possible  role  of  the
LOXL1  variants  in  BRVO.  As  a  result,  the  significant
difference  observed  in  rs1048661  between  the  case  and
control  groups  was  canceled  in  the  analyses  between  the
BRVO EX- and CT groups, suggesting that the percentage of
the population at risk of EX is not significantly higher in the
BRVO  group.  A  retrospective  chart  review  reported
exfoliation material deposits in 6.0% of eyes with BRVO and
6.9% of eyes with CRVO [19], suggesting a lesser extent of
BRVO than CRVO in these subjects, since the BRVO/CRVO
ratio  was  3.2  in  the  general  population  [29].  By  clinical
observation of consecutive cases, the prevalence rates of EX
were 8.2% in eyes with BRVO and 20.8% in eyes with CRVO
compared  with  5.2%  in  control  eyes;  thus  the  authors
concluded that EX is likely a risk factor for CRVO [20]. A
retrospective chart review showed that RVO occurs more
frequently in eyes more affected by EX, and that the most
frequent type of RVO that occurred in EX was CRVO (50%)
followed by about half that prevalence of BRVO (28%) [23].
In this study, the prevalence rate of EX was 14% in eyes with
BRVO from consecutive cases, which may be higher than the
rate of EX in BRVO cases and normal control subjects in
previous reports [19,20]. Differences in the race or age of
subjects may explain the discrepancy, but this needs to be
clarified. Taken together with previous studies, our results
suggest that there is no direct role of LOXL1 variants or EX
in the development of BRVO in our Japanese subjects.
In  summary,  we  tested  the  possible  association  of
LOXL1 variants with BRVO. We did not find an association
between BRVO and EX if the LOXL1 variants were used as
disease markers for clinically undetectable EX.
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